**Recent patent applications in antiviral vaccines**

[Table](#Tab1){ref-type="table"} Table 1Recent patent applications in antiviral vaccinesPatent \#SubjectAssignee(s)Inventor(s)Priority application datePublication dateWO 200589792A new recombinant protein comprising polypeptides bearing epitopes of human papilloma virus (HPV) antigens; useful for treating or preventing HPV infection, or for immunotherapy against the onset of malignant transformation due to HPV infection.BT Pharma (Labège-Innopole, France); INSERM (France); Institut Pasteur (Paris); CNRS (France)la Dant D, le Clerc C, Preville X, Timmerman B3/18/20049/29/2005WO 200587813A new composition that comprises contacting an antigen-presenting cell with a chimeric antigen comprising an immune response domain and a target binding domain, which comprises a xenotypic antibody fragment; useful for eliciting a T-cell response against hepatitis B virus and hepatitis C virus infections.ViRexx (Edmonton, Alberta, Canada)George R, Noujaim A, Tyrrell L, Wang D2/24/20049/22/2005WO 200587799A new isolated polypeptide that binds specifically to an oligosaccharide; useful in preparing a vaccine for treating or preventing HIV infection.US Dept. of Health & Human Services (Washington, DC, USA)Bewley CA3/9/20049/22/2005US 20050202045A method for making a recombinant avian herpesvirus, comprising cotransfecting overlapping subgenomic fragments employing the subgenomic clones and enzymes; useful in producing therapeutic or prophylactic vaccines.Schering-Plough Veterinary Corp. (Kenilworth, NJ, USA)Cochran MD, Cook SM, Wild MA6/14/20019/15/2005WO 200585445A novel recombinant varicella herpes-zoster virus comprising a bacterial artificial chromosome vector sequence; useful as a vaccine for treating varicella herpes-zoster virus infection.Osaka University (Osaka, Japan)Gomi Y, Mori Y, Nagaike K, Takahashi M, Yamaishi K3/5/20049/15/2005EP 1574517A novel recombinant or synthetic hepatitis C virus E1 envelope protein or its portion comprising one or more disulfide bonds between a specific pair of cysteines; useful as vaccine for hepatitis C virus.Innogenetics (Ghent, Belgium)Bosman A, Depla E, Depraetere S, Verheyden G3/9/20049/14/2005WO 200581716A novel nucleic acid encoding chimeric polypeptides such as calreticulin and antigenic peptide from severe acute respiratory syndrome (SARS) coronavirus; useful as a DNA vaccine for SARS coronavirus.Johns Hopkins University (Baltimore, MD, USA)Hung C, Kim TW, Wu T11/24/20039/9/2005CN 1616654A method for inactivating and purifying SARS virus; useful for preparing vaccines to combat SARS.Kexing Biological Products (Shenzen, China)Han Z, Zhang J, Zhang Z11/12/20035/18/2005CN 1616491A new fusion protein useful as a vaccine for treating and preventing influenza.Qinghua University (Beijing)Chen Y; Liu W9/29/20045/18/2005CN 1614011A totally enclosed double-circulating column chromatography process for purifying inactivated virus vaccines.Jiahe Biotechnology (Guangzhou, China)He C; Le W11/6/20035/11/2005CN 1613503A technique for preparing a virus vaccine using a bioreactor featuring a disk carrier for increasing the surface area used to grow cells, and a better culture condition created for increasing the culture density.Jiahe Biotechnology (Guangzhou, China)He C, Zhang J11/6/20035/11/2005IN 200200194Liposomes containing novel peptide antigens; useful for regulating the immune response and for the development of therapeutic agents for the prevention and treatment of hepatitis B virus--associated diseases.Mogam Biotechnology Research Institute (Yongin, South Korea)Chang JS, Cheong H, Cho SY, Choi MJ, Hwang Y, Kim TY, Lee KU4/3/20023/11/2005Source: Thomson Scientific Search Service (formerly Derwent). The status of each application is slightly different from country to country. For further details, contact Thomson Scientific, 1725 Duke Street, Suite 250, Alexandria, Virginia 22314, USA. Tel: 1 (800) DERWENT (<http://www.thomson.com/scientific>).
